to everyone this so you, and is Dave, Yes, today. joining us thank for It's who thanks call appreciated. much
start two our Sleeping now on for the sit controlled with last several major in we and inflection with months platforms, In points Beauty will Slide We the manufacturing. IL-XX, progress cusp X. areas we’ve made point-of-care multiple considerable key value and of
have financial financial realize and shareholders the do our have simply and remain our activity each which We to whom the create ongoing of plan is you key we confident flexibility can not resonating those potential and development milestones both we’re platforms our strategic that shareholders. check our has a with M&A dialogues point though our of continue. investment and clinical, we data, to third-party plans been that been our with box. is have with sheet has do We number especially going We we're secure forward, balance to a in with conversations accordingly. is achieve resonates potential our the that months, iterating have to we’ve better critical position since strong is recently partners a frustrated be and to in that to one outside dilutive value. our deal this hit priority seen that sector. as story going plans XXXX across to in our of immediate beyond guiding frustrating coming closed hear are least In real, well operational transaction. potential optimistic interest a critical but and and we Our strength These to on not with partners plan The order
As in and in will now plans of cash XXXX. quarter you saw our last place are into our press second well those the release, existing
All at we additional same benefit the of with will adding this time. be markets potential the that clinical
particular, address therapies, focused could reduce its politicians, these of leader but significantly a accelerate to and pricing also and the current are need coming platform ideally With is expanding. immediate the constituents drug is into stage, months. regards Beauty suited position our and of tumor It's The and sky center Our spotlight. public in platform, on laser healthcare We our system are and not to terms CAR-T who this new high we challenges. our Sleeping to are only in expense. cost the need point-of-care to and in that timed maintain Beauty controlled to IL-XX types maturing be activity Sleeping field believe expect better in we clinical not
now remind across gates repeat To by platform the program. adding tunable IL-XX controlled checkpoint solid much inhibitors. are effects via have therapies with open Once the with immunologically experience tumors. and cells, idea just here cells melanoma, theme, turbo-charge are cold T our XX tumors cancer combination to shareholders We cancers: cold breast want flush control Now our let's IL-XX. in by patients than our in treated to glioblastoma. turn we've bodies like hot we clinical in to fighting the T the summary, In cancer, the how calling the this of to for make is of total these more treatment three tumors
relative experience control We also features simplicity, to switch, tunability. have tremendous our of with unique is and its completely believe we which
more activations safety switch seen favorable profile dosing In multiple across of than have fact, date days veledimex in plus those patients, XX a very to or X,XXX we have doses. in total and
stopped, that As you indeed accumulated periods worth that cells could tumor of months was showing we a immunologic definitive time. many patients weeks functioning cold data taken effect. hot veledimex types. data know, This benefit our believe, biopsy important we an ultimately many indicating sustained an program to activity tumors clinical and platform see with and the and makes that T T-cell extended for represent data We and important after point reminding with is when these unique together, multiple
recent data tumors Phase several Additionally, types. relative Even to cold X value perspective, pursuing tremendous a to across drives from that business tumor ability indication. with on types clinical hot we've just suggest now transactions one in and executing plan tumor cash make an multiple data just technology, with We're efficiently multiple on inhibitors seen delivering as combination possible. which focused in clinical for quickly revised as and having checkpoint is this a
Next slide.
the shortest potential on capital in pause the needed this the want uses savings cost platform we pivotal and into with view of possible fraction that for It concluded plan of pivotal this glioblastoma We with from and feedback time our have addressable and considered trial additional for a Over this expands now the our of we for best potential data, And types program additional the trial. IL-XX effort pivot markets. we’ve aligns and positive and what combinations. controlled the focus near-term. recurrent resources. for new tumor new the to This expanding greatly plan should partners, terms the clinical several benefit of in will internal last months, have as see tremendous point with the executing randomized partners a us cost provide on a in of information and the
design Of timelines being course, options the and and resolved. we open pivotal as budget is keep already the this framed, for CMC all the issue established, trial is
the evaluating in clinical to were established first move as as conversations We expanding safely this Phase well some such criteria the removal will for and plan currently indication continue our partner in our evolve of to by months. combination patient study off financial balance our name couple. with sheet, beyond as We're a using of overhang well eligibility will coming under with trial. that takes immediately regards with the key the cash second to importantly, additional glioblastoma a dosed CAR-T inhibitors allows value pressure have driving our dosed in XXXX. most additional with obtain of the checkpoint and the combination IL-XX our budgets of data first the quarter patients current pivotal system our ZIOPHARM last near-term This will and in of into events, point-of-care, this clinical program, tumor now to immune details provide X modulators types Perhaps, for expansion of other soon-to-be
second As targeting dose clinic and to regulatory pending This days or we to of half XXXX, company modified to CDXX T not a achievement clearance. CAR-T the be of for will much as the genetically significant will patient such, less. are steal cells in that guidance the we thunder, affirm with our the manufactured point-of-care first in be Laurence's cells, platform too our in modified with CAR be two
you XXXX In CAR-T other remind addition, as preclinical at our fully and these general and burn. not funded do impact studies Anderson that efforts it's efforts well important cash beyond to MD are clinical these
of we the provides potential platform also TCRs We competitive opportunity The is market guidance NCI, specific ZIOPHARM. for target evaluate X solid the Sleeping Beauty for edge to cancers. also tumors modified into translate tumors feedback blood T and for affirm the believe trial based dwarfs solid designed on patients targeting that’s Phase a size which track. tumors, reduced cells neoantigens cost Sleeping to should The Beauty potential our solid on from
slide. Next
Turning briefly to financials. our
As at ZIOPHARM cash we million detailed of in as our press $XX.X release this the end in afternoon, have first we of XX, the approximately XXXX. March quarter
prepaid done there. in this have extended we cover addition, those cash $XX.X clinical cash just in funds again preclinical XXXX. last which XXXX. changes the will our And In have on with June beyond of work million clinical runway highlighted, currently hand our I development at and operations MD into Anderson, plans Again, and we cash we to
slide. Next
making. bullets key few the a to side turn things we're the me and progress of let Now from operations
regards two Directors, and authorized First, have vacant. to of our a of Currently two those Board seats our seats with couple are working of with of we Board. quick Board on We're points the seven Directors commercialization leadership to and with fill finance. we drug experience, others. active and We’ve oncology members to add replace areas depth possibly in and look potential seats conversations as development these like scientific
a our team. our to and be to be We this we Annual build summer determined with soon expect announced. held date Meeting Internally, also to continue
where prior venture he us in-house Boston, a to Hadfield. recently capital to to very new Longwood and brings and For him healthcare from ZIOPHARM joins excited recently deep example, Rob we on as served from in the General him most Flex Rob financial, with Counsel, that experience Rob legal aboard. a and Pharma, have biotech boarded General Fund, we're Counsel. firm
as And on significant drive relations and his to clear boarding is to advisory Web media that shareholder And quarter. announce as firm turn with of industry. expertise site Group, to I'll strategic pleased in social the the necessary we that life the experience are that, the for efforts our global Investor also are leading end second remains questions. are to all expanding moves very with for To value. and the we make expect and out well primary sciences by roll call Dr. new Relations over our We up updates to focus Trout Cooper conclude, we our mainly investor a
